Loading...
•
Jun 30, 2022
Immunic Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
Key Takeaways
Immunic reported its second quarter 2022 financial results, highlighting progress in key clinical programs and setting the stage for important data readouts in the second half of the year. The company's cash and cash equivalents are expected to fund operations into the fourth quarter of 2023.
Initial clinical activity data from IMU-935 in psoriasis is expected in the fourth quarter.
Unblinded safety data from the Phase 1 trial of IMU-856 in healthy human subjects is expected in the third quarter.
Top-line data from the Phase 2 CALDOSE-1 trial of vidofludimus calcium in ulcerative colitis did not meet its primary endpoint due to an interaction with steroid use.
Immunic remains optimistic about vidofludimus calcium's potential in relapsing multiple sclerosis based on data from the EMPhASIS trial.
Forward Guidance
Immunic anticipates clinical milestones for IMU-935 and IMU-856.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...